Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels
Gavin J. Blake, MB, MSc, MRCP*,
Paul M. Ridker, MD, MPH*,* and
Karen M. Kuntz, ScD
,*
* Center for Cardiovascular Disease Prevention, Cardiovascular Division, Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, USA;
Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA

View larger version (13K):
[in a new window]
|
Figure 1 Gains in life expectancy among men (A) and women (B) in the low-density lipoprotein (LDL)/high C-reactive protein (CRP) group, according to the rate of myocardial infarction (MI) and efficacy of statin therapy for the prevention of MI in the low LDL/high CRP group. Line with triangles = 60% efficacy; line with circles = 45% efficacy; line with squares = 30% efficacy. AFCAPS/TexCAPS = Air Force/Texas Coronary Atherosclerosis Prevention Study; WOSCOPS = West of Scotland Coronary Prevention Study.
|
|

View larger version (11K):
[in a new window]
|
Figure 2 Results of sensitivity analysis. Each bar indicates the effect on estimated gains in life expectancy associated with statin therapy in 58-year-old men and women in the low-density lipoprotein (LDL)/high C-reactive protein (CRP) group, when a range of different values (shown in parentheses) is used for the indicated variables. The results for men are shown by solid bars and the results for women by open bars. MI = myocardial infarction.
|
|
Copyright © 2002 by the American College of Cardiology Foundation.